# B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer

> **NCT03953833** · PHASE1 · COMPLETED · sponsor: **Shanghai Pharmaceuticals Holding Co., Ltd** · enrollment: 30 (actual)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **BIOLOGICAL:** Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.

## Key facts

- **NCT ID:** NCT03953833
- **Lead sponsor:** Shanghai Pharmaceuticals Holding Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-01
- **Primary completion:** 2023-01-13
- **Final completion:** 2023-01-13
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03953833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03953833, "B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT03953833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*